U.K.'s Cost Regulator Wants Allergan To Compare Ozurdex With Avastin In Macular Edema
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE says it is "minded" to reject Allergan's Ozurdex but might be persuaded it is stacks up well against off-label Avastin use.
You may also be interested in...
NICE Recommends Ozurdex For Macular Edema; Off-Label Comparative Analysis Carries The Day
Allergan's intravitreal dexamethasone implant cleared by NICE for use in the NHS for macular edema; survives comparison with intravitreal Avastin with equivocal data.
NICE Recommends Ozurdex For Macular Edema; Off-Label Comparative Analysis Carries The Day
Allergan's intravitreal dexamethasone implant cleared by NICE for use in the NHS for macular edema; survives comparison with intravitreal Avastin with equivocal data.
U.K.'s NICE Rejects Lucentis For Macular Edema; Avastin Remains Poised For Appraisal
NICE's preliminary rejection of Lucentis for macular edema paves the way for cheaper Avastin to swallow up most of the U.K. market.